High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
Abstract | UNLABELLED: Thirty-two patients with multiple myeloma were treated with high doses of 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid ( DOTMP) and were a subset of patients enrolled in a multicenter phase I/II dose escalation myeloablative trial. 166Ho with beta-emission (half-life, 26.8 h; beta-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; gamma-photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate. Pharmacokinetics, dosimetry, and biodistribution were studied. METHODS: Patients were treated at escalating dose levels of 20, 30, and 40 Gy to the bone marrow in combination with high-dose melphalan, with or without total-body irradiation, to evaluate toxicity and efficacy. After infusion with 1,110 MBq (30 mCi) of 166Ho-DOTMP for evaluation of biodistribution and dosimetry calculation, patients received the calculated amount of radioactivity for therapy in a single administration based on estimated dose calculations. RESULTS: Thirty-two patients participated in the study and were then treated. The average amount of administered radioactivity was 74.3 GBq (2,007 mCi) (range, 21.5-147.5 GBq [581-3,987 mCi]) of 166Ho-DOTMP. CONCLUSION: 166Ho-DOTMP has physical and pharmacokinetic characteristics compatible with high-dose myeloablative treatment of multiple myeloma.
|
Authors | Joseph G Rajendran, Janet F Eary, William Bensinger, Larry D Durack, Cheryl Vernon, Alan Fritzberg |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 43
Issue 10
Pg. 1383-90
(Oct 2002)
ISSN: 0161-5505 [Print] United States |
PMID | 12368378
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Organophosphorus Compounds
- Radioisotopes
- 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)
- Melphalan
- Holmium
|
Topics |
- Antineoplastic Agents, Alkylating
(administration & dosage, therapeutic use)
- Bone Marrow Purging
- Female
- Holmium
(administration & dosage, therapeutic use)
- Humans
- Male
- Melphalan
(administration & dosage, therapeutic use)
- Middle Aged
- Multiple Myeloma
(radiotherapy)
- Organophosphorus Compounds
(administration & dosage, pharmacokinetics, therapeutic use)
- Radioisotopes
(administration & dosage, pharmacokinetics, therapeutic use)
- Radiometry
- Radiotherapy Dosage
- Tissue Distribution
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|